# data[].attributes.body
This is freely available online. It's a great resource for patients. At TPCH, we have printed copies available in our cardiology ward and they are provided to patients.

# data[].attributes.attachment_link.title
QRCode for Introduction to Hospital Pharmacy Workshop Sign in (1)

# data[].attributes.body
Freely available online. Great resource for patients. At TPCH, we have printed copies available in our cardiology ward and they are provided to patients.

# data[].attributes.headline
Heart Failure Medication Optimisation Plan

# data[].attributes.subject
Heart Failure Medication Optimisation Plan

# data[].attributes.body
If you understand the content in this 2 page document you will be well on your way to ensuring your HFrEF patients get the right therapy!

# data[].attributes.attachment_link.title
Heart Failure Medication Optimisation Plan

# data[].attributes.body
Having a plan to manage fluid is essential for all HF patients!

# data[].attributes.body
This is the link to a basic VTE prophylaxis course i n iLEARN You will need to login on a QH computer to access this

# data[].attributes.attachment_link.title
Alcohol Addiction - Therapeutic Guidelines

# data[].attributes.headline
Alcohol Addiction & Thiamine Supplementation - eTG

# data[].attributes.subject
Alcohol Addiction & Thiamine Supplementation - eTG

# data[].attributes.attachment_link.title
Alcohol Addiction Harm Reduction with Thiamine Supplementation - Therapeutic Guidelines

# data[].attributes.attachment_link.title
11b. ieMR Pharmacist Steps for Discharge Reconciliation

# data[].attributes.attachment_link.title
Winckel K and Santini C. Potassium and magnesium, they go hand in hand. Australian Pharmacist 2024

# data[].attributes.attachment_link.title
Winckel K and Santini C. Sodium and Calcium, the other important electrolytes. Australian Pharmacist 2024

# data[].attributes.headline
ANZCA guideline - perioperative diabetes and hyperglycemic management

# data[].attributes.subject
ANZCA guideline - perioperative diabetes and hyperglycemic management

# data[].attributes.body
This can be handy when managing adult peritonitis patients.

# data[].attributes.attachment_link.title
Renal resources for health professionals

# data[].attributes.body
This is the current version of the Queensland Statewide Aminoglycoside Dosing in Adults Guideline. It is currently undergoing review and update.

# data[].attributes.headline
Children's Health Queensland - AMS Guidelines 

# data[].attributes.subject
Children's Health Queensland - AMS Guidelines 

# data[].attributes.headline
Immunisation Schedule for funded vaccines in Queensland

# data[].attributes.subject
Immunisation Schedule for funded vaccines in Queensland

# data[].attributes.body
This schedule covers all funded (state and NIP) programs for immunisation across the life-span in Queensland.

# data[].attributes.attachment_link.readable_text
The Immunisation Schedule Queensland - July 2020 (current to date), details the eligibility for National Immunisation Program (NIP) funded vaccines and state-funded vaccines.
Immunisation Schedule Queensland 2020 Adolescents & Adults Immunisation Schedule Queensland 2020 Children
From 1 July 2020 there are changes to the immunisation schedule. The changes are designed to improve protection against meningococcal and pneumococcal disease, as well as Haemophilus influenzae type b. In order to accommodate these changes, there are also changes to the hepatitis A vaccination schedule for Aboriginal and Torres Strait Islander children.

Extensive resources to assist you can be found at Clinical update: National Immunisation Program (NIP) schedule changes from 1 July 2020 - advice for vaccination providers Australian Government Department of Health.

Pneumococcal Program

From 1 July 2020 there are changes to the timing, type and number of pneumococcal vaccines given under the NIP. These apply to the following groups:

children and adults with conditions that increase their risk of pneumococcal disease

Aboriginal and Torres Strait Islander children.

all Aboriginal and Torres Strait Islander people aged 50 years and older.

all non-Indigenous people aged 70 years and older.

The list of conditions associated with an increased risk of pneumococcal disease has been updated. There is now a single list of risk conditions for funded NIP pneumococcal vaccination.

For further details go to the Australian Immunisation Handbook

Meningococcal Program

From 1 July 2020, recommendations for meningococcal vaccines have changed to make meningococcal vaccines more readily available and give extra protection to people who are most at risk of invasive meningococcal disease. Recommendations for the use of meningococcal vaccines, including scheduling and dose requirements, remain unchanged. However, some of the recommended vaccine doses are now funded under the NIP. For further information refer to the Australian Immunisation Handbook

Meningococcal B (Bexsero®) and meningococcal ACWY (Nimenrix®) vaccines are funded for people of all ages with medical conditions associated with the highest risk of invasive meningococcal disease, namely; asplenia and hyposplenia, complement deficiency and those receiving treatment with eculizumab. People with ongoing increased risk of invasive meningococcal disease due to these specified medical conditions are also eligible for NIP-funded booster doses of MenACWY vaccine as recommended in the Australian Immunisation Handbook. Also, refer to theATAGI clinical advice on changes to recommendations for the use and funding of meningococcal vaccines from 1 July 2020

Meningococcal B

From 1 July 2020 the meningococcal B vaccine (Bexsero®) are available for Aboriginal and Torres Strait Islander infants at 2, 4 and 12 months of age. An additional dose at 6 months of age is required for Aboriginal and Torres Strait Islander infants with specified medical conditions

A catch-up program is also available until June 2023 (up to 23 months) for Aboriginal and Torres Strait Islander children under 2 years of age. These children can receive Bexsero® at the same time as other vaccines currently included on the NIP schedule.

Meningococcal B vaccine is also available under the NIP for any individual with a medical condition associated with an increased risk of invasive meningococcal disease.

Meningococcal ACWY

Under the NIP, the meningococcal ACWY vaccine is provided for free to:

children at 12 months of age

year 10 students through the School Immunisation Program

young adults aged 15 to 19 years through their doctor or immunisation provider.

From 1 July 2020, meningococcal ACWY vaccine (Nimenrix®) is funded under the NIP for people of all ages with certain medical conditions that increase their risk of invasive meningococcal disease.

Haemophilus influenzae type b vaccine (Hib)

Under the NIP Hib is provided as a routine vaccination for

infants at 18 months of age

as of 1 July 2020, Hib vaccine, ActHIB®, is now funded under the NIP for adults and children >5 years of age with asplenia and hyposplenia.

For further information go to the ATAGI clinical advice on vaccine recommendations for people with risk conditions from 1 July 2020or the Australian Immunisation Handbook

Annual influenza program

Annual vaccination is the most important measure to prevent influenza and its complications and is recommended for all people aged 6 months and over. Queensland Health coordinates the implementation of the National Influenza Immunisation Program in Queensland, which includes distributing influenza vaccine to over 1,800 Queensland vaccine service providers. These providers administer free flu vaccine to eligible groups. For further details on this program visit the Queensland Health Influenza Vaccination Guidelines

You can also visit the Australian Immunisation Handbook for further information about influenza vaccinations.

COVID 19 and Influenza

There are currently no vaccines that protect against COVID-19.

Whilst influenza vaccine will not prevent coronavirus infection it can reduce the severity and spread of influenza, which may make a person more susceptible to other respiratory illnesses like coronavirus

Whooping cough and influenza vaccination for pregnant women

Whooping cough vaccination for pregnant women is offered as part of the NIP. Vaccination is recommended with each pregnancy to provide maximum protection for newborn babies. This includes pregnancies which are close together (e.g. less than 2 years).

The online Australian Immunisation Handbook recommends vaccination of pregnant women (between 20 and 32 weeks).

Pregnant women should also ensure they are vaccinated for influenza (flu), which can safely be given at the same time as the whooping cough vaccine. For the best protection against flu pregnant women who receive an influenza vaccine late in the influenza season should be re-vaccinated if the next season's vaccine becomes available before the end of their pregnancy. However, they must wait until week 20 of their pregnancy to receive the whooping cough vaccine. Women should not delay receiving the influenza vaccine so they can have it at the same time as the whooping cough vaccine.

National Shingles Vaccination Program

The National Shingles Vaccination Program provides a shingles vaccination for adults 70 years of age, with a single catch-up dose funded for adults aged 71 to 79 years until 2021.

Hepatitis B

Hepatitis B vaccine is funded for the groups listed under the NIP including:

low-birth weight preterm newborn infants (less than 2,000g) and/or infants born at less than 32 weeks gestation (irrespective of weight), should also receive a booster of a hepatitis B-containing vaccine at 12 months of age

hepatitis B vaccine is also funded for the following groups, if non-immune/not previously vaccinated:

household or other close (household-like) contacts of people with hepatitis B

sexual contacts of people with hepatitis B

migrants (who have a Medicare card) from hepatitis B endemic countries

Aboriginal and Torres Strait Islander people

people with chronic liver disease and/or hepatitis C

people who inject drugs.

Hepatitis B vaccine is recommended (but not funded) for other individuals who may be at risk of hepatitis B. Refer to the online Australian Immunisation Handbook for further details.

Catch-up vaccines for all children and adolescents up to 19 years

Catch-up immunisations aim to provide optimal protection against disease as quickly as possible by completing the vaccinations recommended for a person.

Immunisation providers should actively review a patient's vaccination history on the Australian Immunisation Register (AIR) and give the appropriate catch-up vaccines as recommended in the online edition of The Australian Immunisation Handbook. An appropriate catch-up schedule cannot be administered without first checking a person's vaccination history.

If a person has not received all the vaccines in the Immunisation Schedule Queensland appropriate for their age, plan and document a catch-up schedule for them.

National Immunisation Catch-up Calculator

A National Immunisation Catch-up Calculator (NICC) for children up to 10 years of age has been released by the Australian Government Department of Health.

Immunisation providers and parents are able to input key information such as the following to determine the catch up vaccination schedule required:

name, address and date of birth

indigenous status

past vaccination history, by either antigen or vaccine names.

The catch-up calculation output can be printed in hard copy.

The NICC has been developed by the Australian Government Department of Health to replace the current immunisation calculator hosted on the South Australian Department of Health website.

National Immunisation Program schedule changes will be incorporated into the calculator. Future releases of the NICC will focus on expanding to people over the age of 10.

# data[].attributes.attachment_link.description
The Immunisation Schedule Queensland - July 2020 (current to date), details the eligibility for National Immunisation Program (NIP) funded vaccines and state-funded vaccines. Immunisation Schedule Queensland 2020 Adolescents & Adults Immunisation Schedule Queensland 2020 Children From 1 July 2020 there are changes to the immunisation schedule.

# data[].attributes.attachment_link.description
MSHPrescribe gives you access to evidence based guidelines, calculators, conversion tables and more.

# data[].attributes.body
This contains a summary of the extensive updates that occurred in December 2025 for the Antibiotic TG.

# data[].attributes.attachment_link.readable_text
What's New in Antibiotic

March 2025

The Antibiotic guidelines provide advice on managing almost 200 unique infections; from self-limiting infections treated in primary care, to life-threatening infections requiring intensive care support. This review of the guidelines has been staggered, with 3 main groupings of topics.

1. Topics completely revised or newly developed for the March 2025 release.

2. Topics under revision that will be published later in 2025 or 2026. To ensure alignment across the guidelines, some of these topics have been amended in the March 2025 release (identified by an amended date on the topic's page).

3. Topics that have recently undergone a complete review and did not require further comprehensive review for the March 2025 release. To ensure alignment across the guidelines, some of these topics have been amended in the March 2025 release (identified by an amended date on the topic's page).

For important changes in this release, see:

Guideline-wide changes for changes impacting multiple topics.

New content and updates to revised topics for a selection of key updates and new content;

Areas in which evidence was lacking, insufficient or conflicting, and for which further research is warranted were identified during this update. To support the research community, these evidence gaps are available on our website.

Guideline-wide changes

The following changes have been made across the Antibiotic guidelines, including topics under revision and previously revised topics, but not in other guideline titles where antimicrobials are recommended.

Whenever an antimicrobial that requires dosage adjustment in kidney impairment is recommended for treatment of infection in adults, a link has been added from the drug recommendation to the advice on dosage adjustment. Links are not included if the antimicrobial does not require dosage adjustment, or for children.

Whenever an antimicrobial that requires dosage adjustment in kidney impairment is recommended for surgical orendocarditis prophylaxis in adults, advice is included in the drug recommendation. Advice is not included if the antimicrobial does not require dosage adjustment when used as a single perioperative dose.

The following changes have been made across the Antibiotic guidelines, including topics under revision and previously revised topics, and in other guideline titles where antimicrobials are recommended.

Intravenous amoxicillin+clavulanate dosages have been updated to include dosage options for both formulations in adults and children who weigh more 40 kg.

In children, adherence to a 6-hourly dosage regimen of cefalexin can be difficult. To address this issue, some cefalexin recommendations (eg for cellulitis andpyelonephritis) now include an option for 8-hourly dosing using a higher dose.

Doxycycline recommendations are now included for the treatment of infections in children younger than 8 years, provided the duration of therapy is less than 21 days (eg for bronchiectasis exacerbations). When used short term, doxycycline has not been associated with tooth discolouration, enamel hypoplasia or bone deposition.

To ensure adequate drug exposure in critically-ill patients, a higher initial dosage of meropenem is recommended for treatment of suspected or confirmed infection withPseudomonas aeruginosa, Burkholderia pseudomallei or Acinetobacter baumannii, because some isolates have a high minimum inhibitory concentration (MIC).

For suspected or confirmed pseudomonal infections, administering piperacillin+tazobactam over 3 hours is preferred to ensure adequate drug exposure. If this is not possible (eg the patient is receiving other drugs via the same line), administration over 30 minutes is an alternative.

When meropenem orpiperacillin+tazobactam is used in critically ill patients, administering the total daily dose as a continuous infusion over 24 hours is preferred to ensure adequate drug exposure.

In hospitalised patients with severe immediate penicillin hypersensitivity, a cephalosporin is recommended for initial intravenous therapy for infection where there are superior treatment outcomes with beta-lactam therapy.

Aminoglycoside dose recommendations for treatment of infection have been updated for adults and children. For adults, lean body weight is recommended to calculate the aminoglycoside dose except when aminoglycosides are used for synergistic therapy of endocarditis or surgical prophylaxis. Aminoglycoside initial dose calculators for treatment of infection in adults have been developed foramikacin, gentamicin and tobramycin. These calculators cannot be used for synergistic therapy or surgical prophylaxis.

Back to top of page.

New content and updates to revised topics

A selection of important changes in the topics completely revised or newly developed for the March 2025 release.

Changes impacting multiple topics

When aminoglycosides are recommended for treatment of infection, tobramycin is now included alongside gentamicin. Tobramycin and gentamicin are ranked equally except if Pseudomonas aeruginosa is suspected or proven, in which case tobramycin is preferred.

For directed therapy of Staphylococcus aureus infections (eg bacteraemia,pneumonia,staphylococcal scalded skin syndrome), cefazolin is now recommended as an equal first-line alternative to flucloxacillin. Evidence suggests that cefazolin is equally effective for methicillin-susceptibleS. aureus and it may have a lower risk of acute kidney injury.

For directed therapy of P. aeruginosa infections (eg pneumonia,bacteraemia or sepsis, bronchiectasis exacerbations inadults andchildren), cefepime is now recommended alongside ceftazidime or piperacillin+tazobactam as an antipseudomonal beta lactam.

To ensure adequate drug exposure, oral amoxicillin+clavulanate 875+125 mg dosed 8-hourly is now recommended for serious infections that are suspected or confirmed to be caused by Enterobacterales orHaemophilus influenzae when either adequate source control has not been achieved, or intravenous to oral switch occurs early.

A 2 g daily dose of ceftriaxone is increasingly recommended but a 1 g daily dose continues to be recommended in specific scenarios; an explanation of the variety of doses used has been included.

In this update, ceftriaxone is usually preferred to cefotaxime in adults because ceftriaxone requires less frequent dosing. If S. aureus is a likely pathogen, cefotaxime monotherapy may be recommended because it has superior intrinsic activity against staphylococci. If ceftriaxone is used in this situation, it is combined with flucloxacillin.

Rates of resistance to clindamycin are rising in methicillin-resistant Staphylococcus aureus (MRSA). For intravenous therapy of serious infections caused by MRSA (eg suspected staphylococcal septic arthritis of a native joint), vancomycin is preferred to clindamycin. However, in some regions, based on local susceptibility data, clindamycin may be a suitable alternative. For oral therapy of MRSA infections, trimethoprim+sulfamethoxazole is usually preferred to clindamycin because of a favourable resistance profile; it also has better palatability in children.

Cardiovascular infections

Commentary on the role of partial oral therapy for infective endocarditis is included.

New content has been developed on managing infective endocarditis in people who inject drugs, because injecting drug use is a common predisposing factor for infective endocarditis. Details are included on the likely pathogens in this population, and specific management considerations for staphylococcal endocarditis. A printable patient information sheet details how to use drugs more safely to reduce risk of infection.

For patients with a cardiac implantable electronic device and bacteraemia, new advice details the approach to management when a cardiac implantable electronic device infection is suspected but not proven.

A new topic on infections associated with intravenous catheters has been developed, providing advice on the management of a suspected bloodstream infection or local infection associated with an intravenous catheter.

Cryptococcosis

Management of cryptococcosis (both pulmonary cryptococcosis and cryptococcal meningitis) is now included in a single topic to improve usability.

Back to top of page.

Infectious diarrhoea

Faecal testing advice has been extensively updated, with new tables summarising indications for standard and specific faecal testing.

The initial management of acute infectious diarrhoea has been updated to prioritise supportive care and close follow-up, and limit antibiotic use in the Australian setting.

Empirical antibiotic therapy for travellers' diarrhoea is no longer recommended for patients with moderate diarrhoea unless they are at increased risk of complications. Antibiotic therapy continues to be an option for patients with severe travellers' diarrhoea.

Management of Clostridioides difficile infection differs in adults and children, and is further influenced by the severity of infection and whether it is a first episode or a recurrence. To aid navigation to the correct treatment regimen, algorithms have been developed for managing a new episode of diarrhoea in patients with risk factors for C. difficile infection.

For treatment of a first episode of mild to moderate C. difficile infection, vancomycin is now recommended first line, because evidence suggests vancomycin has greater efficacy than metronidazole.

Cervical lymphadenitis

Management of cervical lymphadenitis depends on the age of the patient and duration of symptoms; the scope of this topic has expanded to include management advice for adults and a new section on subacute cervical lymphadenitis.

Eye infections

Images of dacryocystitis anddendritic ulcer have been included to aid with diagnosis.

New printable handouts on eyelid hygiene for blepharitis are available to support patients to perform this key aspect of treatment.

Management advice for chlamydial and gonococcal conjunctivitis in neonates and children has been expanded.

To assist with diagnosis and management, a new table describes the comparative features and investigations for the different types of infectious keratitis.

Orbital (postseptal) cellulitis is an emergency but its features overlap with those of periorbital (preseptal) cellulitis. To support prompt diagnosis and escalation of therapy, distinguishing features of each infection are listed in a new table and are integrated into anew management algorithm.

Back to top of page.

Genital and sexually transmissible infections

HIV

New content on indicator conditions for HIV testing has been added to the guidelines. All patients with indicator conditions should be offered HIV testing. Indicator conditions and the need for HIV testing are identified throughout the guidelines in relevant clinical topics (eg cryptococcal meningitis).

Intra-abdominal infections

A shorter duration of therapy is now recommended for many intra-abdominal infections, if adequate surgical source control is achieved.

The role of nonoperative treatment for acute uncomplicated appendicitis is discussed and accompanied by a new algorithm that outlines the approach to managing acute uncomplicated appendicitis and helps assess the appropriateness of nonoperative treatment.

Back to top of page.

Pneumonia

To improve usability, the pneumonia topics have been significantly restructured. To find the right pneumonia topic in these guidelines, see Figure 2.46.

Community-acquired pneumonia (CAP)

Rather than using pneumonia severity scoring tools to assess the severity of CAP in adults, the Antibiotic Expert Group recommend using the features that may indicate hospital admission and the red flags for intensive care support.

A new table provides clearer guidance on the clinical and microbiological investigations for CAP in adults, depending on the severity of pneumonia.

Management of CAP in tropical regions of Australia has been integrated into the standard treatment topics to support routine consideration of pathogens commonly seen in these areas (eg Burkholderia pseudomallei, Acinetobacter baumannii).

Advice on the approach to empirical antiviral therapy for suspected viral CAP has been added.

Intravenous hydrocortisone is recommended within 24 hours of diagnosis for critically unwell adults with high-severity CAP who require high-flow oxygen or mechanical ventilation (invasive or noninvasive), or if there is a concurrent indication for use (eg a COPD exacerbation).

Hospital-acquired pneumonia (HAP)

The definition of hospital-acquired pneumonia has been updated to include patients who have been discharged within the previous 7 days from a hospital admission of longer than 48 hours, as well as patients hospitalised in acute care for longer than 48 hours.

The definition of high-severity HAP has been clarified, noting that patients with sepsis are always considered to have high-severity HAP.

The criteria for using intravenous therapy in patients with low- to moderate-severity HAP have been updated.

Ventilator-associated pneumonia (VAP)

The empirical therapy regimens for ventilator-associated pneumonia are now stratified according to the risk ofPseudomonas aeruginosa. Monotherapy with ceftriaxone or cefotaxime is recommended for patients considered at low risk of P. aeruginosa. For patients at increased risk of P. aeruginosa who receive antipseudomonal therapy initially, a step-down to narrower-spectrum intravenous therapy is no longer recommended. Instead, there is a greater emphasis on reviewing the diagnosis of VAP at 48 hours, and stopping therapy if there is no strong evidence to support the diagnosis.

Directed therapy for pneumonia

The need to treat a broad range of oral anaerobes (eg Bacteroides and Prevotella species) in patients with suspected aspiration pneumonia is often overestimated. A new algorithm outlines the management of patients who have had an aspiration event. A secondalgorithm outlines the management of aspiration pneumonia in patients who are not improving on initial antibiotic therapy.

Back to top of page.

Respiratory infections other than pneumonia

Antibiotic management of bronchiectasis

Bronchiectasis is potentially reversible in children so there is greater emphasis on referral to paediatric respiratory specialists, discussing management decisions with the treating specialist, using individualised management plans and eradicating newly identified Pseudomonas aeruginosa.

For both adults and children, new directed therapy recommendations are included for bronchiectasis exacerbations caused byHaemophilus influenzae, Moraxella catarrhalis, Streptococcus pneumoniae and P. aeruginosa.

Antibiotic management of chronic obstructive pulmonary disease (COPD) exacerbations

Antibiotic therapy is not routinely recommended for COPD exacerbations. A new algorithm helps clinicians to determine when to use antibiotic therapy.

Parapneumonic effusion and thoracic empyema

New advice has been added on the management of thoracic empyema complicating thoracic trauma or haemothorax, complicating long-term indwelling pleural catheter, secondary to haematogenous seeding, and associated with surgical site infection.

Back to top of page.

Prehospital management of meningitis and sepsis

Quick reference tables have been added that provide reconstitution and administration advice for ceftriaxone and benzylpenicillin for the pre-hospital management of patients with suspected meningitis orsepsis.

Sepsis and septic shock

A tiered approach to the timing of antimicrobial administration in patients with suspected sepsis has been implemented. The urgency of antimicrobial administration is influenced by whether the patient has septic shock, is immunocompromised or otherwise vulnerable to sepsis, and the certainty that organ dysfunction is due to infection.

The empirical regimens for sepsis or septic shock of unknown source are published in a suite of 5 topics that span a range of patient groups. New flowcharts are included to help navigation to the correct topic.

Drug recommendations have been added for hospital-acquired sepsis or septic shock in neonates and children younger than 2 months, andchildren 2 months or older.

For adults with community-acquired sepsis without septic shock who do not require intensive care support, a reduced dosing frequency of flucloxacillin andcefazolin is now recommended. Patients with septic shock or requiring intensive care support require more frequent dosing to ensure adequate drug exposure because they are more likely to have low serum albumin, impaired kidney function and be infected with a pathogen with a higher minimum inhibitory concentration (MIC).

Skin and soft tissue infections

Indications for initial intravenous therapy for cellulitis and erysipelas have been updated and simplified.

Cut-off periods for starting antiviral therapy for chickenpox in adults who are immunocompetent have been replaced with a recommendation to start antiviral therapy within 24 hours of rash onset for maximum benefit.

For mild infections of diabetes-related foot ulcers, a new algorithm outlines how to assess the risk of polymicrobial infection and guides antibiotic selection. The suggested duration of therapy is outlined innew tables that consider the degree of resection or debridement, location, and severity and extent of initial or residual infection.

Assessment and management of impetigo include a consideration of the patient's risk of acute rheumatic fever, the nature (nonbullous or bullous) and number of sores, and whether the infection is recurrent. Images of bullous and nonbullous impetigo have been included to aid diagnosis.

New advice has been added on managing staphylococcal scalded skin syndrome in children.

Back to top of page.

Urinary tract infections in adults

More detailed advice is now included on nonantibiotic therapy, as an alternative to antibiotic therapy, for acute cystitis in nonpregnant females younger than 65 years. The expanded text discusses potential benefits and harms of initial nonantibiotic therapy, as well as patient selection.

Nitrofurantoin is now recommended as the first-line treatment of acute cystitis in adults because of high trimethoprim resistance among Escherichia coli.

Changes made to the management of acute pyelonephritis in adults include:

Expanding the patient group for whom oral antibiotics can be used. Initial oral antibiotic therapy can usually be used for nonpregnant adults without sepsis or septic shock who can tolerate and absorb oral therapy.

Intravenous amoxicillin or ampicillin is no longer recommended as part of combination therapy for nonpregnant adults because of high resistance rates among E. coli and rare involvement of enterococci. Amoxicillin or ampicillin (with an aminoglycoside) continues to be recommended in pregnancy because of the increased risk of invasive group B streptococcus [GBS] infection.

Management of sepsis and septic shock from a urinary tract source in adults emphasises consideration of local resistance patterns and patient risk factors for infection with a resistant pathogen. Antibiotic regimens are separated into 3 sections, depending on the presence of pregnancy and septic shock.

To minimise the use of continuous antibiotic prophylaxis for recurrent UTI in nonpregnant adults, nonantibiotic strategies, intermittent postcoital prophylaxis and patient-initiated treatment are emphasised.

Urinary tract infections in children

Managing suspected infection with a multidrug-resistant gram-negative bacterium

Principles of vancomycin use in young infants and children

Back to top of page.

Principles of vancomycin use in adults

Penicillin hypersensitivity

Interim updates to topics under revision

In response to changes made to topics completely revised or newly developed for the March 2025 release, the following changes have been made to some topics under revision:

Back to top of page.

# data[].attributes.attachment_link.description
March 2025 The Antibiotic guidelines provide advice on managing almost 200 unique infections; from self-limiting infections treated in primary care, to life-threatening infections requiring intensive care support. This review of the guidelines has been staggered, with 3 main groupings of topics. Topics completely revised or newly developed for the March 2025 release.

# data[].attributes.headline
Herston Infectious Diseases Institute (HeIDI)TDM Guideline

# data[].attributes.subject
Herston Infectious Diseases Institute (HeIDI)TDM Guideline

# data[].attributes.body
This is a really handy guide that provides information on TDM for many antimicrobials.

# data[].attributes.headline
YouTube Vids - Antibiotic Updates from eTG

# data[].attributes.subject
YouTube Vids - Antibiotic Updates from eTG

# data[].attributes.body
This link should take you to a page with a number of interesting TG updates that were presented at the ASID conference in April 2025. You may need to go to the main TG page to see the rest of the recordings in the series. This is just here in case you are ever looking for something to listen to in the car or on the train. Please do not feel that you need to watch these videos before the weekend!

# data[].attributes.attachment_link.title
Updated sepsis recommendations in adults | Dr Edward Raby | ASID Pre-Conference Symposium

# data[].attributes.headline
LFTs - Analgesia for the cirrhotic patient

# data[].attributes.subject
LFTs - Analgesia for the cirrhotic patient

# data[].attributes.attachment_link.title
Analgesia for the cirrhotic patient  A literature review and recommendations

# data[].attributes.attachment_link.title
Estimation of kidney function for medication dosing in adult patients with